ArticleImmunoHorizons2026
TGF-β-induced Tregs release extracellular vesicles that modulate CD4+ T-cell proliferation and phenotype in a Nrp1-dependent manner.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Periodontitis with Treg-Derived Extracellular Vesicles: Modulation of Macrophages and CD8International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuropilin-1 (Nrp1) is one of the receptors for TGF-β and is associated with the suppressive function of T regulatory cells (Tregs). Based on previous findings on natural Tregs, this work investigated the role of Nrp1 on induced Tregs (iTregs) and their small extracellular vesicles (sEVs) by using a conditional knockout for Nrp1 on FoxP3+ cells. sEVs derived from iTregs were obtained by ultracentrifugation, purified using size exclusion columns, and characterized by nanoparticle tracking analysis. sEVs' impact on CD4+ T-cell cultures was evaluated using functional modulation assays, including CD4+ T-cell phenotypic analysis by flow cytometry and ELISA. We observed a decrease in iTreg induction when CD4+ T cells came from the Nrp1 knockout (KO) mice, indicating that Nrp1 is required for de novo FoxP3 induction/expression. Second, CD4+ T cells cultured with sEV-derived from wild-type (WT) iTregs reduced CD4+ T-cell proliferation, decreased the expression of CD25, and induced FoxP3 and CD73. In contrast, sEVs derived from Nrp1KO iTregs were unable to suppress CD4+ T-cell proliferation and to favor CD25 and CD73 expression. With respect to cytokine production, both sEVs derived from WT and Nrp1KO iTregs inhibited IL-10 and IFN-γ secretion, indicating that Nrp1 is not required for the regulation of these cytokines by sEV. Overall, this study provides new information into the role of Nrp1 in immunomodulation, revealing that Nrp1 signaling plays a role in iTreg differentiation by permitting FoxP3 expression and that iTreg-derived sEVs depend on Nrp1 to control CD4+ T-cell proliferation and phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.